证券代码：688520 证券简称：神州细胞 北京神州细胞生物技术集团股份公司 投资者关系活动记录表 编号：2023-053 特定对象调研 分析师会议 投资者关系 媒体采访 业绩说明会 活动类别 新闻发布会 路演活动 现场参观 其他 时间 11月10日 10:00-12:00 华福证券、诺安基金、中邮资管 参与单位 14:00-16:00 禹田资本 地点 公司会议室 唐黎明（董事、副总经理、董事会秘书） 接待人员 投资者关系 一、公司近况 活动主要 内容介绍 公司已披露2023年第三季度报告，主要财务指标情况如下： ...

证券代码：688520 证券简称：神州细胞 北京神州细胞生物技术集团股份公司 投资者关系活动记录表 编号：2023-052 特定对象调研 分析师会议 投资者关系 媒体采访 业绩说明会 活动类别 新闻发布会 路演活动 现场参观 其他 时间 11月6日10:00-11:00 地点 上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/） 谢良志（董事长、总经理）；唐黎明（董事、副总经理、董事会秘书）；马洁 接待人员 （财务总监）；王晓川（独立董事） 投资者关系 公司于 2023 年 11 月 6 日 10:00-11:00 在上海证券交易所上证路演中心（网 活动主要 内容介绍 址：http://roadshow.sseinfo.com/）以网络互动的方式召开 2023年第三季度业 绩说明会，具体问题如下： ...

证券代码：688520 证券简称：神州细胞 生多大影响，公司将会如何调整产品相关的战略？ A：安佳因®自上市以来，以其良好的产品质量、综合性价比优势，赢得了患 者的信任，牢牢占据了市场领先地位。我们将密切关注竞争产品上市给安佳 因®带来的影响，积极应对，以满足患者和市场关切。 Q3：请问今年公司是否有双抗会申请临床？ A： 公司有较为成熟的双抗产品开发平台，多个产品处于临床前研究阶段。 后续临床申请请关注公司相关信息披露。 Q4：安佳因®今年年初获批儿童适应症后，来源于安佳因®的收入是否有显著 变化？ A：安佳因®销售收入还处于上升中，大部分还是来自于成人患者。目前已有 部分儿童患者持续使用安佳因®，趋势良好，我们预计未来儿童患者对营收的 贡献会逐步提升。 北京神州细胞生物技术集团股份公司 投资者关系活动记录表 编号：2023-052 | | 特定对象调研 分析师会议 | | --- | --- | | 投资者关系 | 业绩说明会 媒体采访 | | 活动类别 | 新闻发布会 路演活动 | | | 现场参观 其他 | | 时间 | 11 月 6 日 10:00-11:00 | | 地点 | 上海 ...

证券代码：688520 证券简称：神州细胞 北京神州细胞生物技术集团股份公司 投资者关系活动记录表 编号：2023-051 特定对象调研 分析师会议 投资者关系 媒体采访 业绩说明会 活动类别 新闻发布会 路演活动 现场参观 其他 时间 11月1日-11月2日 11月1日14:00-15:40 国泰君安、国寿安保、沣京资本、中金资管、Orbimed 11月1日15:50-17:30 中泰证券、人保养老、建信理财、远信投资、兴合基 参与单位 金、禹田资本、惠升基金 11月2日10:00-11:00 开源医药、财通基金、安信基金 地点 公司会议室、电话会议 唐黎明（董事、副总经理、董事会秘书） 接待人员 投资者关系 一、公司近况 ...

证券代码：688520 证券简称：神州细胞 北京神州细胞生物技术集团股份公司 投资者关系活动记录表 编号：2023-051 特定对象调研 分析师会议 投资者关系 媒体采访 业绩说明会 活动类别 新闻发布会 路演活动 现场参观 其他 时间 11月1日-11月2日 11月1日14:00-15:30 中泰资管 15:00-17:00 中信证券、建信股权、相聚资本、中加基金、东海证券、和聚投 参与单位 资、盘京投资、成都廪实基金、华杰高景、财通基金、国融自营、知合基金、 逸原达投资、大成基金 11月2日10:00-11:00 开源医药、财通基金、安信基金 地点 公司会议室、电话会议 唐黎明（董事、副总经理、董事会秘书） 接待人员 投资者关系 ...

Financial Performance - The company's operating revenue for Q3 2023 reached ¥571,176,343.36, representing a 108.21% increase compared to the same period last year[4]. - The net profit attributable to shareholders of the listed company was -¥82,106,803.14 for Q3 2023, with a year-to-date net profit of -¥219,964,027.34[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥31,483,643.75 for Q3 2023, showing significant improvement[5]. - The company reported a net cash flow from operating activities of -¥373,677,900.53 year-to-date, indicating ongoing cash flow challenges[5]. - The company reported a total of 271,212,760 shares held by the largest shareholder, accounting for 60.90% of total shares[10]. - The company reported a gross profit margin of approximately 3.5% for Q3 2023, down from 6.5% in Q3 2022, reflecting a decline in profitability[17]. - The net loss for Q3 2023 was ¥220,383,751.08, an improvement compared to a net loss of ¥403,460,333.75 in Q3 2022, showing a reduction of about 45.2%[19]. - In Q3 2023, the company reported a net loss attributable to the parent company of CNY -220,031,701.72, compared to a loss of CNY -402,620,817.82 in the same period last year, indicating an improvement of approximately 45%[20]. - The basic and diluted earnings per share for Q3 2023 were both CNY -0.49, an improvement from CNY -0.92 in Q3 2022[20]. Research and Development - Research and development expenses totaled ¥316,969,129.31 for Q3 2023, accounting for 55.49% of operating revenue, indicating a 17.61% increase in R&D investment[5]. - The R&D investment increased significantly as several products entered critical clinical stages, leading to higher funding requirements[8]. - R&D expenses in Q3 2023 amounted to ¥806,115,168.18, up from ¥605,125,368.48 in Q3 2022, reflecting a growth of approximately 33.2%[19]. - The company plans to continue investing in new product development and market expansion strategies to drive future growth[19]. Assets and Liabilities - The total assets of the company as of the end of Q3 2023 were ¥2,847,595,362.67, reflecting a 4.08% increase from the end of the previous year[5]. - Total assets as of Q3 2023 were ¥2,847,595,362.67, slightly up from ¥2,735,875,608.33 in the previous year, marking an increase of approximately 4.1%[16]. - Total liabilities increased to ¥3,286,694,027.77 in Q3 2023 from ¥2,978,066,553.77 in Q3 2022, representing a rise of about 10.3%[16]. - The company's equity attributable to shareholders was reported at -¥433,138,935.20 in Q3 2023, worsening from -¥236,650,939.28 in Q3 2022[16]. - Short-term borrowings rose to ¥827,419,033.27 in Q3 2023, compared to ¥508,449,216.36 in Q3 2022, indicating an increase of approximately 62.8%[16]. Cash Flow and Investments - Cash inflow from operating activities totaled CNY 1,399,193,356.76, a significant increase from CNY 715,295,203.21 in the previous year, representing a growth of approximately 95%[21]. - The net cash outflow from operating activities was CNY -373,677,900.53, slightly worse than the previous year's outflow of CNY -365,865,528.04[21]. - Investment activities generated a net cash outflow of CNY -412,354,804.44, compared to CNY -667,727,629.82 in the same period last year, showing a reduction in cash outflow by approximately 38%[23]. - The company raised CNY 1,358,027,023.53 through financing activities, an increase from CNY 730,365,853.82 in the previous year, marking an increase of about 86%[23]. - The total cash and cash equivalents at the end of Q3 2023 stood at CNY 409,079,124.06, up from CNY 300,797,066.69 at the end of Q3 2022[23]. - The company received CNY 1,033,000,000.00 from investment recoveries, down from CNY 2,111,000,000.00 in the previous year, indicating a decrease of approximately 51%[21]. - The company reported a total cash outflow from investment activities of CNY 1,449,003,026.78, compared to CNY 2,782,373,035.21 in the same period last year, reflecting a decrease of about 48%[23]. Market and Strategic Focus - The company’s revenue growth was driven by strong market expansion and competitive advantages in production capacity and cost[8]. - The company continues to focus on expanding its market presence and enhancing its product pipeline to drive future growth[8]. - The company has not disclosed any new product or technology developments in this quarter[12]. - There are no significant mergers or acquisitions reported during this period[12]. - The company has not provided specific future guidance or market expansion strategies in the current report[12].

证券代码：688520 证券简称：神州细胞 公告编号：2023-034 北京神州细胞生物技术集团股份公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2023 年 10 月 30 日(星期一) 至 11 月 03 日(星期五)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sinocelltech.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 北京神州细胞生物技术集团股份公司（以下简称"公司"）已于 2023 年 10 月 28 日在上海证券交易所网站（www.sse.com.cn）披露了公司 2023 年第三季度 报告。为便于广大投资者更全面深入地了解公司 2023 年第三季度经营成果、财 务状况，公司计划于 2023 年 11 月 06 日上午 10:00-11:00 举行 202 ...

中信证券股份有限公司关于 北京神州细胞生物技术集团股份公司 2023 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京神州细 胞生物技术集团股份公司（以下简称"神州细胞"或"公司"）持续督导阶段的保荐机 构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》 （以下简称"《上市规则》"）等相关规定，出具 2023 年半年度（以下简称"本持续 督导期"）持续督导跟踪报告。 1 一、持续督导工作情况 序号 工作内容 实施情况 1 建立健全并有效执行持续督导工作制度，并针对具体的持 续督导工作计划制定相应的工作计划 保荐机构已建立健全并有效 执行了持续督导制度，并制 定了相应的工作计划 2 根据中国证监会相关规定，在持续督导工作开始前，与上 市公司签署持续督导协议，明确双方在持续督导期间的权 利义务，并报上海证券交易所备案 保荐机构已与神州细胞签订 承销及保荐协议，该协议明 确了双方在持续督导期间的 权利和义务，并已报上海证 券交易所备案 3 持续督导期间，按照有关规定对上市公司违法违规事项公 开发表声明的，应于披露前向上海证券交易所报告，并经 上海 ...

证券代码：688520 证券简称：神州细胞 公告编号：2023-033 重要内容提示： （http://roadshow.sseinfo.com/） 投资者可于 2023 年 9 月 6 日(星期三)16:00 前通过公司电话或邮箱 ir@sinocelltech.com 将需要了解和关注的问题提前提供给公司。公司将在说明会 上对投资者普遍关注的问题进行回答。 北京神州细胞生物技术集团股份公司（以下简称"公司"）已于 2023 年 8 月 23 日在上海证券交易所网站（www.sse.com.cn）披露了公司 2023 年半年度报 告。为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状 况、发展理念，公司参与了由上交所主办的 2023 年半年度制药及生物制品行业 集体业绩说明会，此次活动将采用网络文字互动的方式举行，投资者可登录上海 证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 本次投资者说明会以网络文字互动方式召开，公司将针对 2023 年半年度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2023, representing a 20% increase compared to the same period last year[2]. - The company reported a significant increase in revenue, achieving a total of 500 million in the first half of 2023, representing a 25% growth compared to the same period last year[12]. - Total revenue for the first half of 2023 reached CNY 808.08 million, representing a year-on-year growth of 114.91%[48]. - The company's operating revenue for the first half of 2023 reached ¥808,075,290.81, an increase of 114.91% compared to ¥376,009,837.38 in the same period last year[72]. - The net profit attributable to shareholders was a loss of ¥137,857,224.20, an improvement from a loss of ¥250,341,256.26 in the previous year[17]. - The company reported a net profit margin of 15% for the first half of 2023, indicating improved operational efficiency[12]. - The net cash flow from operating activities was a negative ¥175,233,048.38, compared to a negative ¥240,169,415.35 in the same period last year[17]. - The company's cash and cash equivalents decreased by 43.22% to ¥551,866,933.04, down from ¥971,884,878.41[75]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 1.2 million users by the end of June 2023[2]. - User data showed a 30% increase in active users, reaching 1.2 million by the end of June 2023[12]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[2]. - The company is focusing on market expansion in Europe, targeting a 15% increase in market penetration by the end of 2024[12]. Research and Development - Research and development expenses increased by 30% to 100 million CNY, focusing on the development of new biopharmaceutical products[2]. - Research and development expenses increased by 10%, totaling 50 million, reflecting the company's commitment to innovation[12]. - The company reported a total R&D investment of approximately ¥547.62 million, a 39.70% increase compared to ¥392.01 million in the same period last year[38]. - The company's R&D expenditure accounted for 67.77% of its revenue, a decrease of 36.49 percentage points from 104.26% in the previous year[19]. - The company has 791 R&D personnel, representing 38.23% of the total workforce, an increase from 716 personnel in the same period last year[43]. - The average salary for R&D personnel increased to 14.03 thousand CNY, up from 13.44 thousand CNY in the previous year[43]. Product Development and Approvals - New product launches included a novel antibody therapy, expected to enter clinical trials by Q4 2023, which could expand the company's market share significantly[12]. - The company has launched 1 recombinant protein drug and 3 monoclonal antibody products, with 2 vaccine products included for emergency use[21]. - The product Anjain® (recombinant human coagulation factor VIII) was approved for additional indications in January 2023, targeting bleeding control in children with hemophilia A[21]. - The COVID-19 vaccine SCTV01E has been included for emergency use in both China and the UAE, with positive results from clinical trials indicating good efficacy against Omicron variants[22]. - The company has launched two biosimilars, Anjairun® and Anbeizhu®, in June 2023, with approvals for multiple indications[22]. - The company has completed communication with the National Medical Products Administration regarding the Phase III clinical research plan for the SCT1000 project (14-valent HPV vaccine) and is currently preparing for patient enrollment[23]. - The SCT-110A product (PD-1 monoclonal antibody) has completed patient enrollment for two indications: first-line treatment of liver cancer and head and neck cancer[23]. - The SCT650C product (IL-17 monoclonal antibody injection) has obtained Phase Ia clinical trial filing in Australia and has initiated patient enrollment[23]. - The company has established a production line with a total capacity of 22,000L for commercial production, with an additional 20,000L production line under construction[25]. Strategic Partnerships and Acquisitions - A strategic partnership was established with a leading biotechnology firm to enhance product development capabilities[2]. - The company announced a strategic partnership with a leading biotech firm to enhance its product pipeline and accelerate development timelines[12]. - The company is exploring potential acquisitions to strengthen its position in the oncology market, with a budget of up to 200 million allocated for this purpose[12]. Compliance and Governance - The company has no significant risks impacting its operations during the reporting period, ensuring stable performance[4]. - There were no non-operational fund occupations by controlling shareholders or related parties during the reporting period[5]. - The board of directors confirmed that all members attended the board meeting, ensuring governance compliance[4]. - The company is committed to improving corporate governance and compliance awareness among employees to support long-term development[56]. Environmental and Social Responsibility - The company has updated its emergency response plan for environmental incidents and has filed it with government departments, conducting regular drills to mitigate impacts[92]. - The company has implemented real-time monitoring for wastewater pollutants, including COD and ammonia nitrogen, and conducted multiple monitoring sessions for various emissions sources[93]. - The company has adopted energy-saving technologies, such as variable frequency air conditioning systems and high-efficiency lighting, to reduce greenhouse gas emissions[95]. - The company has committed to a 36-month lock-up period for its major shareholders following the IPO, ensuring stability in shareholding[97]. Risks and Challenges - The company anticipates continued losses in the second half of 2023 due to ongoing investments in R&D and marketing for new products[58]. - The company is facing risks related to market competition and pricing pressures, particularly for its flagship product, Anjain®[60]. - The company faces uncertainties in preclinical research outcomes, which may impact the ability to recover research costs and affect financial performance[61]. - The company is facing risks related to raw material shortages and is working on improving supply chain management to ensure stable procurement[65]. Shareholder Commitments and Stability - The actual controller, Xie Liangzhi, has committed not to transfer or entrust the management of shares held before the IPO for 36 months from the date of listing[99]. - The controlling shareholder, Lasa Ailike, has made a similar commitment regarding share transfers for 36 months post-listing[99]. - The company has received commitments from multiple shareholders to not transfer shares for specified periods, ensuring stability post-IPO[106]. - The company will bear legal responsibility for any losses incurred due to violations of these commitments[104]. Financial Management and Fund Utilization - The total amount of funds raised for the clinical research projects reached CNY 1,676,530,000, with cumulative investment of CNY 848,786,252.98, achieving a progress rate of 102.05%[177]. - The company has committed to improving its fund management practices to prevent similar errors in the future[180]. - The company has not reported any other significant issues regarding the use of raised funds during the reporting period[181].